171 related articles for article (PubMed ID: 28937434)
1. Th17 Response of Borderline-Lepromatous Leprosy Inhibits Rash Manifestation of Dapsone Hypersensitivity Syndrome: Case Report.
de Nardo Vanzela T; Bernardes Filho F; Wambier CG; Faria FM; Foss NT; Frade MAC
Am J Dermatopathol; 2018 Mar; 40(3):205-208. PubMed ID: 28937434
[TBL] [Abstract][Full Text] [Related]
2. Dapsone hypersensitivity syndrome in a lepromatous leprosy patient--A Case Report.
Gavilanes MC; Palacio AL; Chellini PR; Nery JA; Rego JG
Lepr Rev; 2015 Jun; 86(2):186-90. PubMed ID: 26502691
[TBL] [Abstract][Full Text] [Related]
3. Spared white islands in a drug rash: revisiting sparing phenomenon in Hansen's disease.
Gopinath H; Nayak K; Kumar P; Chakraborti S
Int J Dermatol; 2017 May; 56(5):e102-e104. PubMed ID: 28194775
[No Abstract] [Full Text] [Related]
4. Case Report: Borderline Lepromatous Leprosy Therapy Complicated by Type 1 Leprosy Reaction and Adverse Reactions with Dapsone and Clofazimine.
Matono T; Suzuki S; Mori S; Ato M
Am J Trop Med Hyg; 2024 Mar; 110(3):483-486. PubMed ID: 38266303
[TBL] [Abstract][Full Text] [Related]
5. Fatal dapsone hypersensitivity syndrome with hypothyroidism and steroid-induced diabetes mellitus.
Pai S; Munshi R; Nayak C
Indian J Pharmacol; 2017; 49(5):396-398. PubMed ID: 29515281
[TBL] [Abstract][Full Text] [Related]
6. Dapsone: An Update.
Karjigi S; Murthy SC; Kallappa H; Kusuma MR; Aruna B; Reddy YN
Indian J Lepr; 2016 Sep; 87(4):233-239. PubMed ID: 29762952
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of Prospective HLA-B*13:01 Screening to Prevent Dapsone Hypersensitivity Syndrome in Patients With Leprosy.
Liu H; Wang Z; Bao F; Wang C; Sun L; Zhang H; Yu G; Mi Z; Li J; Li L; Zhao Q; Yue Z; Zhao W; Yu W; Cao J; Xiong F; Wang Y; Chai Z; Cheng X; Zhang Y; Fu F; Lang X; Wang X; Irwanto A; Krismawati H; Fu X; Sun Y; You J; Liu J; Pan Q; Chu T; Liu D; Chen S; Shen J; Yan L; Zhang G; Liu J; Zhang F; ; Xiong L; Yang J; Li J; Ke W; Li M; Ning Y; Xiong J; Li M; Xiong M; Yang B; Duan Q; Wang H; Li W; Kuang Y; Li J; Wang L; Cao Q; Xiao P; Xiao B; Zhang L; Lin Z; Wang Y; Shen Y; Yan L; Wu W; Zheng H; Zhan X; Li W; Shang X; Xu Y; Liu Q
JAMA Dermatol; 2019 Jun; 155(6):666-672. PubMed ID: 30916737
[TBL] [Abstract][Full Text] [Related]
8. Daily multidrug therapy for leprosy; results of a fourteen-year experience.
de Carsalade GY; Wallach D; Spindler E; Pennec J; Cottenot F; Flageul B
Int J Lepr Other Mycobact Dis; 1997 Mar; 65(1):37-44. PubMed ID: 9207752
[TBL] [Abstract][Full Text] [Related]
9. Dapsone syndrome: an incomplete form.
Jaswal R; Thami GP; Kanwar AJ
Indian J Lepr; 1998; 70(2):229-30. PubMed ID: 9724867
[No Abstract] [Full Text] [Related]
10. Dapsone hypersensitivity syndrome in an adolescent during treatment during of leprosy.
Bucaretchi F; Vicente DC; Pereira RM; Tresoldi AT
Rev Inst Med Trop Sao Paulo; 2004; 46(6):331-4. PubMed ID: 15654479
[TBL] [Abstract][Full Text] [Related]
11. Case Report: A Case of Type 1 Leprosy Reaction and Dapsone Hypersensitivity Syndrome Complicating the Clinical Course of Multibacillary Leprosy.
Craig J; MacRae C; Melvin RG; Boggild AK
Am J Trop Med Hyg; 2019 May; 100(5):1145-1148. PubMed ID: 30915953
[TBL] [Abstract][Full Text] [Related]
12. T-cell plasticity of dapsone and DRESS.
Markova A; Duquesnoy R; Levis W
J Drugs Dermatol; 2014 Jan; 13(1):12-3. PubMed ID: 24385113
[No Abstract] [Full Text] [Related]
13. Increase in the incidence of dapsone hypersensitivity syndrome--an appraisal.
Rao PN; Lakshmi TS
Lepr Rev; 2001 Mar; 72(1):57-62. PubMed ID: 11355519
[TBL] [Abstract][Full Text] [Related]
14. Dapsone syndrome in a Filipino man.
Hortaleza AR; Salta-Ramos NG; Barcelona-Tan J; Abad-Venida L
Lepr Rev; 1995 Dec; 66(4):307-13. PubMed ID: 8637384
[TBL] [Abstract][Full Text] [Related]
15. Dapsone induced pulmonary eosinophilia without cutaneous allergic manifestations--an unusual encounter--a case report.
Arunthathi S; Raju S
Acta Leprol; 1998; 11(1):3-5. PubMed ID: 9693685
[TBL] [Abstract][Full Text] [Related]
16. A docking model of dapsone bound to HLA-B*13:01 explains the risk of dapsone hypersensitivity syndrome.
Watanabe H; Watanabe Y; Tashiro Y; Mushiroda T; Ozeki T; Hashizume H; Sueki H; Yamamoto T; Utsunomiya-Tate N; Gouda H; Kusakabe Y
J Dermatol Sci; 2017 Dec; 88(3):320-329. PubMed ID: 28870516
[TBL] [Abstract][Full Text] [Related]
17. Anatopic response: Double sparing phenomenon in a patient with dapsone hypersensitivity syndrome.
Maddala RR; Ghorpade A; Adulkar S; Polavarapu M
Indian J Dermatol Venereol Leprol; 2017; 83(2):241-243. PubMed ID: 27852986
[No Abstract] [Full Text] [Related]
18. Dapsone hypersensitivity syndrome in non-leprosy patients: a retrospective study of its incidence in a tertiary referral center in Taiwan.
Sheen YS; Chu CY; Wang SH; Tsai TF
J Dermatolog Treat; 2009; 20(6):340-3. PubMed ID: 19954390
[TBL] [Abstract][Full Text] [Related]
19. Dapsone hypersensitivity syndrome among leprosy patients in China.
Tian W; Shen J; Zhou M; Yan L; Zhang G
Lepr Rev; 2012 Dec; 83(4):370-7. PubMed ID: 23614255
[TBL] [Abstract][Full Text] [Related]
20. A lethal case of the dapsone hypersensitivity syndrome involving the myocardium.
Hoogeveen RM; van der Bom T; de Boer HH; Thurlings RM; Wind BS; de Vries HJ; van Lent AU; Beuers U; van der Wal AC; Nellen FJ
Neth J Med; 2016 Feb; 74(2):89-92. PubMed ID: 26951355
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
